Presentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds
|
|
|
- Jack Stafford
- 6 years ago
- Views:
Transcription
1 Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy University of Washington Leah Gordon, MD MPH 4/24/15 Question 1 A 60 year old woman with urge incontinence has pursued behavioral modification and pelvic floor training but continues to be bothered by frequent episodes of incontinence and is interested in pharmacologic treatment. She has no other medical problems. She has heard these medications can be expensive and is worried about the potential cost. a. Oxybutynin (Ditropan XL) 30mg po daily b. Fesoterodine (Toviaz) 4mg po daily d. Mirabegron (Myrbetriq) 25mg po daily Question 1 1
2 Answer 1 Which medication would be appropriate to start for her? a. Oxybutynin (Ditropan XL) 30mg po daily b. Fesoterodine (Toviaz) 4mg po daily d. Mirabegron (Myrbetriq) 25mg po daily S P E C I F I C I T Y OXYBUTYNIN = Ditropan FESOTERODINE = Toviaz TOLTERODINE = Detrol SOLIFENACIN = Vesicare DARIFENACIN = Enablex TROSPIUM = Sanctura M 3 Primary Outcomes in Most Studies: Complete Continence = NO incontinent episodes Clinically Important Improvement = reduction in frequency of incontinent episodes by at least 50% Quality of Life All Anti Muscarinics: Many large, well done RCTs BEST effects reduced incontinence or have clinically important improvement in 20% of women. NO big differences in efficacy across meds 2
3 Answer 1 An Approach Start Cheap Side Effects? Specific Cases Which medication would be appropriate to start for her? a. Oxybutynin (Ditropan XL) 30mg po daily b. Fesoterodine (Toviaz) 4mg po daily d. Mirabegron (Myrbetriq) 25mg po daily Question 2 Question 2 A 55 year old woman with urge incontinence as well as atrial fibrillation, depression, and diabetes on Metformin, Fluoxetine, and Metoprolol is interested in starting a medication for her incontinence. a. Darifenacin (Enablex) 7.5mg po daily b. Trospium (Sanctura) 20 mg po daily 3
4 Answer 2 a. Darifenacin (Enablex) 7.5mg po daily b. Trospium (Sanctura) 20 mg po daily Start Cheap Side Effects? Specific Cases Answer 2 Start Cheap Side Effects? Interactions a. Darifenacin (Enablex) 7.5mg po daily b. Trospium (Sanctura) 20 mg po daily Trospium 4
5 Question 3 A 65 year old woman with mixed stress/urge incontinence and no other co morbidities was previously on Trospium without improvement. She is now interested in trying a different medication. switch to for her? a. Oxybutynin (Ditropan) 5mg po daily b. Trospium (Sanctura) 60mg po daily c. Darifenacin (Enablex) 7.5mg po daily Question 3 Answer 3 a. Oxybutynin (Ditropan) 5mg po daily b. Trospium (Sanctura) 60mg po daily c. Darifenacin (Enablex) 7.5mg po daily Start Cheap Side Effects? Prior treatment? Solifenacin 5
6 Answer 3 a. Oxybutynin (Ditropan) 5mg po daily b. Trospium (Sanctura) 60mg po daily c. Darifenacin (Enablex) 7.5mg po daily Question 4 A 60 year old woman with early Alzheimer s disease on Donepezil is very bothered by urge incontinence and wants to start a medication. a. Mirabegron (Myrbetriq) 25mg po daily b. Solabegron mg po daily c. Oxybutynin (Ditropan) 5mg po daily d. Trospium (Sanctura) 60mg po daily Question 4 Answer 4 a. Mirabegron (Myrbetriq) 25mg po daily b. Solabegron mg po daily c. Oxybutynin (Ditropan) 5mg po daily d. Trospium (Sanctura) 60mg po daily 6
7 Beta adrenergics Caution in: Cognitive Impairment Start Cheap Cholinesterase Inhibitors Side Effects? Combination with other strong anti cholinergics Specific Cases Severe Hepatic Failure Dialysis Beta 3 agonists Mirabegron Solabegron Beta adrenergics Beta adrenergics Beta 3 agonists Beta 3 agonists Mirabegron Mirabegron Solabegron Not yet approved in US Mechanism of Action Beta 3 agonsim Relaxes detrusor muscle Data Similar to About 20% response Side Effects Increase in BP Headache Dizziness Tachycardia GI upset NO: dry mouth, blurry vision 7
8 Answer 4 Caution in: Cognitive Impairment Start Cheap Cholinesterase Inhibitors Side Effects? Combination with other strong anti cholinergics Specific Cases Severe Hepatic Failure Dialysis Mirabegron? a. Mirabegron (Myrbetriq) 25mg po daily b. Solabegron mg po daily c. Oxybutynin (Ditropan) 5mg po daily d. Trospium (Sanctura) 60mg po daily References Ellsworth PI. The Pharmacologic Management of Idiopathic Overactive Bladder in Primary Care. J Fam Pract 2014;63:S38. Goode PS. Incontinence in Older Women. JAMA 2010;303:2172. Hoffman BL. Williams Gynecology, 2e. The McGraw Hill Companies, Inc Imran M. Mirabegron for overactive bladder: a novel, first in class B3 agonist therapy. Urol J 2013 Sep 26;10(3): Marinkovic SP. The management of overactive bladder syndrome. BMJ 2012;344: Nygaard I. Idiopathic Urgency Urinary Incontinence. N Engl J Med 2010; 363:1156. Nishizawa O. Guidelines for management of urinary incontinence. Int J Uro 2008;15:857. Qaseem A. Nonsurgical management of urinary incontinence in women: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2014;161: Shamliyan T. Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women. Ann Intern Med 2008;148:459. Shamliyan T. Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women. Ann Intern Med 2012;156:861. Wu J. Prevalence and Trends of Symptomatic Pelvic Floor Disorders in US women. Obstet Gyncol 2014;123:141. 8
Urinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
Overactive Bladder (OAB) Step Therapy Program Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Origination: 07/2013 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for brand name Overactive Bladder
Overactive Bladder (OAB) Step Therapy Program
Overactive Bladder (OAB) Step Therapy Program Policy Number: 5.01.556 Last Review: 11/2018 Origination: 7/2013 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
Is There a Best Drug for Overactive Bladder in a Patient with Dementia?
Is There a Best Drug for Overactive Bladder in a Patient with Dementia? Todd Semla, MS, Pharm.D., BCPS, FCCP, AGSF National PBM Clinical Pharmacy Program Manager Mental Health & Geriatrics U.S. Department
Evaluation & Management of Overactive Bladder
Evaluation & Management of Overactive Bladder Disclosures/Conflict of Interest/Bias I have no financial relationship with any of the companies that produce the products I m about to discuss I have no conflicts
THE OVER-ACTIVE BLADDER (OAB)
THE OVER-ACTIVE BLADDER (OAB) Passage of urine is caused by the bladder muscle contracting coordinated with the relaxation of the sphincter muscles, which is controlled by higher centers in the central
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
Geriatric Urinary Incontinence
Geriatric Urinary Incontinence Neil M. Resnick, MD Thomas Detre Professor of Medicine Chief, Division of Geriatric Medicine University of Pittsburgh/UPMC UI: The Problem Prevalence in elderly 33% Morbidity
Primary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
URGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
Drugs for Overactive Bladder (OAB)
ril 2014 Drugs for Overactive Bladder (OAB) FINAL CONSOLIDATED COMPREHENSIVE RESEARCH PLAN July 2015 FINAL COMPREHENSIVE RESEARCH PLAN 2 A. Introduction The objective of the drug class review on drugs
Overactive Bladder. Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan
Overactive Bladder Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan Speaker Disclosure I have nothing to disclose. 2 Learning Objectives Define OAB Identify
Dr. Melissa Kagarise, PA C
Dr. Melissa Kagarise, PA C This program has been supported by an educational grant from Pfizer Pharmaceuticals PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of
Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
Urinary Incontinence. Lee A. Jennings, MD, MSHS. Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center
Urinary Incontinence Lee A. Jennings, MD, MSHS Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center Slides adapted from Alison Moore, MD, MPH University of
Management of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
CDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
Overactive Bladder. When to see a doctor. Normal bladder function
Overactive Bladder Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary
Evaluation and Treatment of Incontinence
Evaluation and Treatment of Incontinence Classification of Incontinence Failure to empty: Overflow incontinence Failure to store Stress Incontinence Urge Incontinence Physiology of voiding CNS Brain sends
Report on New Patented Drugs - Vesicare
Report on New Patented Drugs - Vesicare Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board's Excessive
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
Rational Pharmacotherapy for LUTS in Older People. Dr William Gibson MBChB MRCP
Rational Pharmacotherapy for LUTS in Older People Dr William Gibson MBChB MRCP Frailty Frailty = state of increased vulnerability resulting from agingassociated decline in reserve and function NOT synonymous
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PROPIVERINE HYDROCHLORIDE (Mictoryl/Mictoryl Pediatric Duchesnay Inc.) Indication: Overactive bladder This document was originally issued on April
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
Urinary Incontinence. Alison A Moore, MD, FACP
Urinary Incontinence Alison A Moore, MD, FACP Professor of Medicine/Geriatric Medicine David Geffen School of Medicine at UCLA Department of Medicine, Division of Geriatrics Urinary Incontinence (UI) Involuntary
Taking Control of your Bladder, or. Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence
Taking Control of your Bladder, or Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence Brett Vassallo, MD, FACOG, FAC Female Pelvic Medicine and Reconstructive
Managing urinary incontinence in the elderly
Managing urinary incontinence in the elderly Cara Tannenbaum, MD, MSc Michel Saucier Endowed Chair Geriatric Pharmacology, Health & Aging Associate Professor of Medicine & Pharmacy, Université de Montréal
Overactive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
Urinary Incontinence: The Neglected Geriatric Syndrome. Dr. Martha Spencer, MD, FRCPC Providence Health Care Clinical Instructor, UBC
Urinary Incontinence: The Neglected Geriatric Syndrome Dr. Martha Spencer, MD, FRCPC Providence Health Care Clinical Instructor, UBC Poll Question 1: Urinary incontinence is an expected consequence of
Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
Urinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
Overactive Bladder: Identifying Patients at Risk, Implementing New Strategies
Overactive Bladder: Identifying Patients at Risk, Implementing New Learning Objectives Identify patients with OAB risk factors in order to proactively initiate a discussion about bladder symptoms and establish
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
Neuromuscular Blocking Agents
Neuromuscular Blocking Agents DRUG POLICY This Prior Authorization request will be reviewed for medical necessity only. Benefits are subject to the terms and conditions of the patient s contract. Please
Drug Class Review Agents for Overactive Bladder
Drug Class Review Agents for Overactive Bladder Final Update 4 Report March 2009 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE
RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE SAAD JUMA, MD INCONTINENCE RESEARCH INSTITUTE ENCINITAS, CA AUA STRESS URINARY INCONTINENCE GUIDELINE UPDATE INDEX PATIENTS The otherwise healthy
SELECTED POSTER PRESENTATIONS
SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL
Urogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office
Urogynecology Office Urogynecology Office Can You Hold? An Update on the Treatment of OAB Can You Hold? Karen Noblett, MD Professor and Chair Department of OB/GYN University of California, Riverside Disclosures
Appendix 2 Drug Information
Appendix 2 Drug Information Chemical Name: baclofen (bak-loe-fen) Brand Name: Lioresal (U.S. and Canada) Description: Baclofen acts on the central nervous system to relieve spasms, cramping, and tightness
Dee E. Fenner, M.D. Chair and Furlong Professor of Women s Health Dept. of Obstetrics and Gynecology University of Michigan.
Management of Overactive Bladder Dee E. Fenner, M.D. Chair and Furlong Professor of Women s Health Dept. of Obstetrics and Gynecology University of Michigan deef@umich.edu Disclosures NONE Objectives Review
ril 2014 FINAL CONSOLIDATED REPORT MARCH 2016 Treatment of Overactive Bladder
ril 2014 FINAL CONSOLIDATED REPORT MARCH 2016 Treatment of Overactive Bladder FINAL REPORT 2 The (ODPRN) is funded to conduct drug class reviews as part of an initiative to modernize the public drug formulary
Bladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
URINARY INCONTINENCE
Center for Continence Care and Pelvic Medicine What is urinary incontinence? URINARY INCONTINENCE Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only
North Georgia Urology Center, P.C. Urology Patient Questionnaire
Today s Date North Georgia Urology Center, P.C. Urology Patient Questionnaire Dear Patients: to help the urologist give you better care, please take a moment of valuable time to answer the following questions.
R. Matthew Smith M.D. Mercy Urology
R. Matthew Smith M.D. Mercy Urology None Disclosures Goals Update growth of Mercy Urology Clinic Quick Review of Hematuria and PSA Present common urologic complaints seen by the primary care physician
Etiology, risk factors, and management overactive bladder : Review
International Journal of Scientific & Engineering Research Volume 9, Issue 1, January-2018 1152 Etiology, risk factors, and management overactive bladder : Review Saud Mohammed Saud Aleisa, Abdulrahman
FDA Briefing Document for Nonprescription Drugs Advisory Committee
FDA Briefing Document for Nonprescription Drugs Advisory Committee Oxybutynin Transdermal System NDA 202211 Proposed Indication: Treats overactive bladder in women Topic: Partial Rx-to-OTC switch for oxybutynin
Some people experience occasional, minor leaks of urine. Others wet their clothes frequently.
Urinary Incontinence Urinary incontinence the loss of bladder control is a common and often embarrassing problem. The severity ranges from occasionally leaking urine when you cough or sneeze to having
Report on New Patented Drugs Enablex
Report on New Patented Drugs Enablex Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
Disclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
The International Urogynecological Association and the
ORIGINAL RESEARCH Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions Alon Yehoshua, PharmD, MS; Brian P. Murray, MD; Sandip P. Vasavada, MD; and Peter
Dr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
I. Uniform Formulary Review Process
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
Uniform Formulary Beneficiary Advisory Panel Handout February 2006
Uniform Formulary Beneficiary Advisory Panel Handout February 2006 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinicaleffectiveness
OVERACTIVE BLADDER (OAB)
OVERACTIVE BLADDER (OAB) Ms Taryn Hallam Alana Health Care for Women Women s Health Training Associates OVERACTIVE BLADDER The most misdiagnosed and misunderstood of all the urinary disorders. Problem???
Urodynamic Studies. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Urodynamic Studies An information guide Urodynamic Test After reading this leaflet we hope that you will have a greater understanding about
Pharmacologic management of overactive bladder
REVIEW Pharmacologic management of overactive bladder Sum Lam 1,2 lga Hilas 1,3 1 St. John s University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, Queens,
NEW DEVELOPMENTS IN HYPERTENSION. Clinical Issues in Geriatrics for Primary Care Practice
Clinical Issues in Geriatrics for Primary Care Practice Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine April 7, 2015 Declaration of full disclosure: No conflict of interest
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
OAB Treatment Guidelines
OAB Treatment Guidelines This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. It is part of the activity Overcoming
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
The Ontario Drug Policy Research Network Drug Class Review on Medications for Overactive Bladder (OAB)
ril 2014 The Drug Class Review on Medications for Overactive Bladder (OAB) FINAL QUALITATIVE REPORT March 2016 Prepared by the ODPRN Knowledge Translation Unit, Li Ka Shing Knowledge Institute Knowledge
Female Urinary Incontinence
Primary Care Internal Medicine Female Urinary Incontinence May Wakamatsu, MD MGH Vincent Obstetrics & Gynecology Dept Division of Female Pelvic Medicine & Reconstructive Surgery 2015 Female Urinary Incontinence
STRATEGIES TO ADDRESS URINARY INCONTINENCE EVERY PHYSICAL THERAPIST SHOULD KNOW
Strategies to Address Urinary Incontinence Every Physical Therapist Should Know Presenter: Wendy M. Featherstone, PT, DPT Presentation recorded on March 30, 2017 www.homehealthsection.org STRATEGIES TO
R. Matthew Smith M.D. Stacy Pohlman, ARNP Jessica Gengler, PT, DPT Mercy Urology
R. Matthew Smith M.D. Stacy Pohlman, ARNP Jessica Gengler, PT, DPT Mercy Urology Disclosures Matt Smith None Stacy Pohlman None Jessica Gengler None Topics Clinical Pathway Development Prostate Cancer
Overactive bladder. Information for patients from Urogynaecology
Overactive bladder Information for patients from Urogynaecology An overactive bladder (OAB) is a very common problem. It can cause distressing symptoms that are difficult to control. These can include
Overactive Bladder beyond antimuscarinics
Overactive Bladder beyond antimuscarinics Marcus Drake Bristol Urological Institute Conflicts of interest; Allergan, AMS, Astellas, Ferring, Pfizer Getting the diagnosis right Improving treatment Improving
The Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis
European Urology European Urology 48 (2005) 5 26 ReviewöOveractive Bladder The Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis Christopher Chapple a, *,
NEW DEVELOPMENTS IN HYPERTENSION
Common Problems in Older Women Using Geriatric Principles in Every Day Practice Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 3, 2013 Declaration of full disclosure:
The International Continence Society
REPORTS Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults Richard G. Roberts, MD, JD; Alan D. Garely, MD; and Tamara Bavendam, MD Abstract This article evaluates
Common Urology. RMH Grand Rounds Feb Greg Harrington h9p://rmurology.com/
Common Urology RMH Grand Rounds Feb 3 2016 Greg Harrington h9p://rmurology.com/ Disclosures Nil ObjecGves review and discuss common urologic condigons Competencies diagnose and treat common urologic condigons
URGENCY INCONTINENCE FLAME LECTURE: 175 BURNS / TABIT
URGENCY INCONTINENCE FLAME LECTURE: 175 BURNS / TABIT 3.17.17 Learning Objectives Discss etiology and risk factors for rge rinary incontinence Describe the workp for rge rinary incontinence Describe management
These drugs produce effects similar to the sympathetic nervous system
Terms adrenergic Drugs mydriasis sympathetic nervous system adrenergic drugs adrenergic mechanism of action positive inotropic effect positive chronotropic effect positive dromotropic effect adrenergic
Urinary incontinence in women & men
Urinary incontinence in women & men Dr. Blayne Welk Assistant Professor, Western University, London, ON, Canada Part 1: INCONTINENCE IN WOMEN Urinary incontinence is common. About 1 in 4 young women, and
STEP THERAPY IN MEDICARE PART D
STEP THERAPY IN MEDICARE PART D Sarkis Kavarian, PharmD Candidate 15 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1 st, 2015 Objectives Why is this important? Medicare Part
Pelvic Floor Disorders and the Geriatric Patient
Pelvic Floor Disorders and the Geriatric Patient Cassandra L. Carberry, MD, MS, FACOG Assistant Professor (Clinical), Ob/Gyn Alpert Medical School of Brown University Director of Clinical Services Division
Urinary incontinence (UI) affects many women in the
Annals of Internal Medicine Review Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women A Systematic Review Tatyana Shamliyan, MD, MS; Jean F. Wyman, PhD; Rema Ramakrishnan,
Prior Authorization Update: Botulinum Toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Mifegymiso. New Exception Status Benefits
OCTOBER 2017 Nova Scotia Formulary Updates Mifegymiso New Exception Status Benefits Prozac (fluoxetine syr) Neupro (rotigotine) Brenzys (etanercept) Changes in Benefit Status Criteria Updates OAB Medications
Safety and Tolerability Profiles of Anticholinergic Agents Used for the Treatment of Overactive Bladder
REVIEW ARTICLE Drug Saf 2011; 34 (9): 733-754 0114-5916/11/0009-0733/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Safety and Tolerability Profiles of Anticholinergic Agents Used for the
SenioRx Care Perspective
CT-ASCP's SenioRx Care Perspective Inside: UCONN Student Chapter Update Page 2 New Choices for an Old Problem: Pages 3-5 Urinary Incontinence Medications in Overactive Bladder Notes n Votes August 2015
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
Latest Press Release. sbn network jimmy swaggart comcast
corp@stantec.com Latest Press Release sbn network jimmy swaggart comcast S i have only been taking optiprostate xts for 8 days and i also take tamsulosin with it. i was taking myrbetriq but it is not all
Possible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic Patients
Med. J. Cairo Univ., Vol. 84, No. 1, March: 85-90, 2016 www.medicaljournalofcairouniversity.net Possible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic
Overactive Bladder Syndrome
Page 1 of 5 Overactive Bladder Syndrome Overactive bladder syndrome is common. Symptoms include an urgent feeling to go to the toilet, going to the toilet frequently, and sometimes leaking urine before
Faculty. Louis Kuritzky, MD Clinical Assistant Professor Department of Community Health & Family Medicine University of Florida Gainesville, FL
OAB Made Simple for the Primary Care Provider (PCP): Emerging Challenges In Primary Care: 2014! OAB Made Simple for the Primary Care Provider (PCP): How to Identify, When to Treat and When to Refer Faculty
Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
OVERACTIVE BLADDER IN THE ELDERLY PATIENT
Program Name: OVERACTIVE BLADDER IN THE ELDERLY PATIENT Planning Committee: John Papastergiou, BScPhm Denise Gélinas, B.Pharm, MBA Surinder Gill, BScPhm Accrediation Information: This version of the program
Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
Drugs for the overactive bladder: are there differences in persistence and compliance?
Editorial Drugs for the overactive bladder: are there differences in persistence and compliance? Karl-Erik Andersson 1,2 1 Institute for Regenerative Medicine, Wake Forest University School of Medicine,
Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline. IDENTITY Citation Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr,
Botulinum Toxins. Length of Authorization: From 90 days to 12 months
Botulinum Toxins Goal(s): Approve botulinum toxins for funded OHP conditions supported by evidence of benefit (eg, dystonia or spasticity associated with certain neurological diseases). Require positive
Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives
Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives Arun Sahai PhD, FRCS (Urol) Consultant Urological Surgeon & Honorary Senior Lecturer Guy s Hospital
Advanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa
Advanced Care for Female Overactive Bladder & Urinary Incontinence Department of Urology Kaiser Permanente Santa Rosa Goals Participants will: Review normal urinary tract anatomy and function Understand
Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply